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Abstract
Plant molecular farming (PMF) is a convenient and cost-effective way to produce high-value
recombinant proteins that can be used in the production of a range of health products, from
pharmaceutical therapeutics to cosmetic products. New plant breeding techniques (NPBTs)
provide a means to enhance PMF systems more quickly and with greater precision than ever
before. However, the feasibility, regulatory standing and social acceptability of both PMF
and NPBTs are in question. This paper explores the perceptions of key stakeholders on
two European Union (EU) Horizon 2020 programmes–Pharma-Factory and Newcotiana–
towards the barriers and facilitators of PMF and NPBTs in Europe. One-on-one qualitative
interviews were undertaken with N = 20 individuals involved in one or both of the two projects
at 16 institutions in seven countries (Belgium, France, Germany, Italy, Israel, Spain and the
UK). The findings indicate that the current EU regulatory environment and the perception of
the public towards biotechnology are seen as the main barriers to scaling-up PMF and
NPBTs. Competition from existing systems and the lack of plant-specific regulations likewise
present challenges for PMF developing beyond its current niche. However, respondents felt
that the communication of the benefits and purpose of NPBT PMF could provide a platform
for improving the social acceptance of genetic modification. The importance of the media in
this process was highlighted. This article also uses the multi-level perspective to explore the
ways in which NPBTs are being legitimated by interested parties and the systemic factors
that have shaped and are continuing to shape the development of PMF in Europe.
Introduction
Plants offer a convenient and cost-effective expression system for the production of high-value
recombinant proteins [1]. Plant molecular farming (PMF) has been used to produce monoclo-
nal antibodies the targeting HIV, Rabies and Ebola viruses [2–5]. PMF can also been used for
the production of nanoparticles for biomedical use [6,7] and compounds for cosmetic pur-
poses [8–10]. These are often referred to as plant-made (or plant-derived) pharmaceuticals,
plant-made industrials, biopharmaceuticals or biologics. For simplicity, the term plant-made
pharmaceuticals (PMPs) is used in this article.
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The demand for such high-value molecules has grown and continues to rise, sometimes
outstripping supply from existing protein expression systems that rely on yeast, bacterial and
mammalian cell cultures [11]. Plants have several advantages over these protein expression sys-
tems, namely: (i) lower production costs; (ii) low risk of contamination with human patho-
gens; (iii) scalability of cultivation; (iv) and expertise and infrastructure in place for the
production of plant material [9,12–15].
At the same time, recent advances in biotechnology are finding plant breeding applications.
These are collectively known as new plant breeding techniques (NPBTs) and can be used to
produce improved crop varieties that would be difficult to obtain by using traditional breeding
methods or transgenic modification [16,17]. The CRISPR-Cas9 system, for example, has
already been used to improve the efficacy of Nicotiana tabacum and N. benthamiana as PMF
platforms [18,19], with CRISPR offering the possibility for rapid development of plant-based
protein expression using generic recipient lines for desired recombinant DNA [20].
Despite the potential of PMF to impact global health [21] and NPBTs to improve PMF
expression systems, previous research has identified several non-technical barriers to the
development of these technologies.
Newcotiana & Pharma-Factory
Two separate but complimentary Horizon 2020 projects include work packages to explore the
social, economic and environmental issues associated with PMF and NPBTs in the EU and
contribute to the responsible development of these innovations.
The Pharma-Factory project (https://pharmafactory.org) is coordinated by St George’s Uni-
versity of London and involves 14 institutions (13 in EU member states and one in Israel). The
project aims to resolve the technical, social and economic bottlenecks for PMF. It takes a prod-
uct-led approach with five small to medium enterprises (SMEs) involved in the production of
medical, veterinary and diagnostic products—it also aims to involve all relevant stakeholders
in the process of developing these platforms, including scientists, representatives of PMF busi-
nesses and the public at large. The public engagement work-package of the Pharma-Factory
project places particular emphasis on facilitating communication between these groups [22],
public engagement and understanding barriers to social acceptance.
The Newcotiana project (https://newcotiana.org) is coordinated by Consejo Superior de
Investigaciones Cientı´ficas (CSIC) in Spain and involves 19 institutions (18 in EU member
states and one in Australia). The programme of work focuses on the application of NPBTs to
improving the tobacco plant (N. tabacum) and its relative (N. benthamiana) as PMF platforms.
It is hoped that these efforts will lead to the tobacco plant becoming a model crop for a variety
of PMP targets, which would in turn lead to shorter development times for new products and
testing. The public engagement work-package of the Newcotiana project aims to engage the
public as well as relevant stakeholders to determine barriers and facilitators of PMF, with a
particular emphasis on understanding attitudes towards NPBTs.
To provide context for these work packages, scoping research was undertaken to develop
an understanding of the perceived barriers and facilitators of PMF amongst key stakeholders
(i.e. those involved in research and development of PMF platforms). Future work expands on
this approach by involving wider groups of stakeholders and the public.
Plant molecular farming
The use of plants as platforms for the expression of recombinant proteins was first demon-
strated in the late 1980s and early 1990s –primarily with the tobacco plant [23–25]. It would
take over a decade for the first commercial product to be launched [8], but since that time a
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large number of products have been commercialised or are in development [9,26]. Today,
PMF relies on a number of methods for protein expression: (i) stable nuclear transformation
of a crop species that will be grown in a field or glasshouse; (ii) stable plastid transformation of
a crop species; (iii) transient transformation of a crop species in containment; and (iv) stable
transformation of a plant species that is grown hydroponically such that the protein is secreted
into the medium and recovered [12]. Each method has its strengths and weaknesses, depend-
ing on target molecule. The short timescales required to produce large amounts of protein via
transient expression makes it suitable for products with irregular demand or unstable markets
[9,27]. The stable transformation of crop species takes much more time, but represents the
most scalable production method [9]–and potentially the most controversial from a social per-
spective. PMF represents the third ‘generation’ of genetically modified (GM) plants: first-gen-
eration crops were bred for productivity, second-generation crops for food quality and third-
generation crops for the production of PMPs and industrial purposes [28,29].
Four factors differentiate PMF from the older, first-generation biotechnology paradigm:
1. Purpose: the aim of PMF differs from the plant breeding of food and feed crops for direct
consumption by humans or animals [30].
2. Non-food status of (some) PMF platforms: the use of non-food/feed crops such as tobacco
may limit the risk of gene transfer to food crops [31] and reduce public concern over con-
tamination [30,32].
3. Transient expression: proteins of interest are extracted without modifying the germline of
plant (instead only modifying the bacteria that infects the plant). These molecules are pro-
duced in contained facilities, which may reduce concerns over contamination [31,33].
4. New plant breeding techniques: NPBTs differ from first-generation transgenic breeding
techniques in terms of precision and, in some cases, do not result in products that contain
transgenic material [16,34].
Despite these factors, PMF is still in the process of gaining the social acceptability currently
enjoyed by rival expression systems [11].
New plant breeding techniques
New plant breeding techniques are a collection of specific biotechnologies that have largely
emerged over the last two decades [35]. These include site-specific nuclease (SSN) technolo-
gies, such as the CRISPR-Cas9 and zinc finger nucleases (ZFNs), so named due to their ability
to modify target genomes at designated points. These techniques are also known as gene edit-
ing/engineering and permit cisgenesis (breeding plants using only genetic material native to
that species or from a sexually compatible relative) and intragenesis (using only genes native to
a particular species or close relative, but in novel combinations).
Whilst NPBTs often rely on an initial transgenic “step”, these techniques can produce plants
with no final transgenic material that are indistinguishable from those bred by conventional
breeding approaches [16,34,36,37]. Crucially, gene editing is viewed by experts as a significant
departure from earlier plant biotechnology because it permits the inactivation of endogenous
genes, precise conversion of alleles and the insertion of whole genetic elements from close rela-
tives [38]. As such, NPBTs have renewed the debate about how to regulate biotechnology by
creating a ‘grey area’ for plant breeding legislation [22].
In the EU, NPBTs have fallen under the umbrella of existing (first-generation, transgenic)
GM legislation (2001/18/EC) [39,40]; the decision of the European Court of Justice (ECJ) in
2018 that directed mutagenesis is covered by this regulation has caused concern amongst the
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European scientific community over the impact to biotechnology investment and commercia-
lisation prospects [41,42]. In the United States and other countries in the Americas, crops bred
with NPBTs have found relatively quick routes to market where regulation is no stricter than
for conventionally-bred crops [43]. These have included crops with targeted gene ‘knockouts’,
such as a non-browning mushroom with reduced polyphenol oxidase production [44]. The
alternate regulatory ‘triggers’ in the EU and in the USA represent the two broad pathways to
regulating modified crops [39]: process- and product-based regulation. A process-based regula-
tory trigger responds to crops produced by specific technologies, as in the EU [39]. A product-
based regulatory trigger responds to products with specific, often “novel” characteristics, such
as transgenes. In practice, the two pathways are both subject to considerable local variations
and exemptions, which Eckerstorfer et al. [39] argue will prevent international harmonisation
in the near future.
The regulatory debate intersects the wider issue of social acceptability and whether the reg-
ulatory approach to NPBTs should address public concerns over the risks of biotechnology or,
where these are considered to be divergent, be based purely on known environmental risks of
such biotechnology [45,46]. Malyska et al. [46] argue that EU legislation on the cultivation of
GM crops was driven largely by public concerns about risk [see also 47], rather than by the
interpretation of scientific evidence. Various theories have been proposed to explain public
reaction to biotechnology in Europe, such as the ‘knowledge deficit’ model, which suggests
that it is a lack of knowledge about science leads to resistance against it. Some authors have
argued that a lack of sufficient information about biotechnology has led to consumers relying
on the advice of ‘other’ stakeholders such as consumer and environmental organisations in the
past [47]. However, this model is not without its criticisms [48,49]. Some studies have found
no association between information deficits and acceptance [50]. Others have found that social
trust is more important than knowledge with respect to public perceptions of new technology
[51]. Besley et al. [52], for example, show an increase in negative attitudes towards scientific
studies that include large commercial partners.
Certain EU directives (2005/412) have meant that member states can unilaterally ‘opt-out’
of GM crop cultivation [53]. The ECJ’s 2018 ruling on NPBTs could lead to member states
employing this opt-out for NPBT-bred crops in the future, with implications for PMF. Yet
questions remain over the social acceptability of PMPs from NPBT plants: do consumers
know or care how these are derived? Ultimately, whilst there has been a substantial academic
effort to understand stakeholder and public attitudes towards first-generation GM food and
feed crops, much less has been done with regards to PMF—and less still at the intersection of
PMF and NPBTs, which has only emerged as a technological pairing in recent years.
The multi-level perspective
As NPBTs test existing European regulation on GM crops, PMF tests regulation that concerns
the production of pharmaceuticals [54,55]. Some commentators have argued that PMPs are
constrained by existing regulation designed for cell culture technology that does not account
for the distinct advantages of plant-based expression systems [56]. Technological trajectories
are often restricted by current standards and past choices that in turn result in new technolo-
gies being “locked out” of a market, independent of the inherent qualities of the technologies
themselves [57–59].
One theoretical framework to understand how new technologies emerge and begin to
challenge the existing socio-technical regime–in this case, bacterial and mammalian protein
expression systems—is the multi-level perspective (MLP). MLP proposes that ‘niches’ repre-
sent spaces in which to develop new technology that are isolated in some way from normal
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market pressures, such as university laboratories [60]. Niche-innovations are often carried and
developed by small networks of what Geels & Schot call ‘dedicated actors’ [61], of which the
PMF community makes an interesting case study. An example of this is the ZMapp Ebola virus
vaccine (Mapp Biopharmaceutical), developed in tobacco (N. benthamiana) to respond to the
2014 Ebola Crisis in West Africa [4]; the lack of cell culture alternatives and speed of protein
acquisition provided an ideal space in which to demonstrate the effectiveness of PMF [62–64].
A further unit of analysis in MLP is the landscape; this is the slow-changing, macro-level
environment in which regimes sit. Changes in the landscape—such as policies supporting
“greener” industrial processes, for example—can exert pressure on the regime, creating oppor-
tunities for niche-innovations to gain market share and change existing modes of business.
The somewhat slow development of PMF products since the idea was first proposed in the
1980s may be explained by a lack of landscape-level pressure [64]. Dolfsma & Leydesdorff [59]
point out that technologies can break out of such conditions if a ‘third’ (i.e. non-market and
non-technological) factor can “unpick” the lock of the existing regime. For PMF, this could be
plant-specific regulations or protocols. Until such regulation is developed, there will be a disin-
centive for commercial development of (some) PMPs [56]. One means by which favourable
policy can be advanced is through legitimation; this is the process by which actors frame issues
in a way that confers legitimacy to their actions or technologies, often by creating positive dis-
courses around their innovation [60]. In the case of PMF, this often relies on comparisons
with existing protein expression systems (e.g. plants being cheaper or more scalable) and the
opportunities to improve health outcomes in low- and middle-income countries [see 65].
There is a need to understand how these factors could influence future health outcomes.
This article describes a qualitative scoping study with key PMF experts, which helped guide
the development of follow-on research for Newcotiana and Pharma-Factory projects public
engagement work.
The research questions framing this initial scoping study were: what are the barriers and
facilitators of PMF and NPBTs in Europe? How are PMF products perceived by experts and
how might they be perceived by end-users? How have PMF experts engaged with the public
about these technologies?
It is hoped that this study will contribute to ongoing discussions about the future of PMF
and emerging debates about the appropriate regulation of NPBTs, as well as provide an initial
framework for understanding the development of both technologies through the multi-level
perspective.
Methodology
The methodology of the study involves two overlapping parts of the Pharma-Factory and New-
cotiana engagement work. Both studies focused on gaining an understanding of the opinions
of stakeholders towards the risks and opportunities of PMF and NPBTs and what might con-
stitute barriers and facilitators to the ongoing development of these technologies. An applied
qualitative approach was employed; the need to understand varied social phenomena necessi-
tated an in-depth understanding of the topic. Qualitative research can provide four classifica-
tions of information [66]:
1. Contextual: describing what exists
2. Explanatory: examining the reasons for and relationships between what exists
3. Evaluative: appraising the effectiveness of what exists
4. Generative: supporting the development of theories, strategies and actions
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Each of these categories is important for understanding the barriers and facilitators for scal-
ing-up PMF. Firstly, a contextual understanding of the practicalities of developing PMF prod-
ucts is required to situate subsequent information. Secondly, explanatory accounts of support
for or opposition to genetic modification, for example, are important. The evaluation of how
well PMF platforms are performing and the perceived suitability of the regulatory environ-
ment in which they currently operate will likewise be valuable. Lastly, generative accounts of
possible facilitation mechanisms will provide a basis for future work on the Pharma-Factory
and Newcotiana projects.
Semi-structured interviews with key consortium stakeholders
Semi-structured one-on-one interviews were chosen as the most suitable method of data gen-
eration for this study on the basis that they can provide the level of depth required to explore
each the categories described above. Semi-structured interviews allow the researcher to probe
interesting lines of inquiry during the interview in a flexible manner [67].
An interview guide was developed for each study (available in the project repositories).
These were created following consultation with the relevant literature on PMF and NPBTs
respectively. An interview guide helps the interviewer structure the interview by orientating it
around topics relevant to the study aims [68]. In the case of Newcotiana, the interview guide
concerned: 1) the risks and benefits of using NPBTs to modify Nicotiana lines 2) personal and
public perceptions of NPBTs and 3) participation in public engagement activities. For
Pharma-Factory, the interview guide was focused on: 1) perceptions of plant-derived products,
2) key stakeholders and end-users for PMPs and 3) experience with stakeholder and end-user
engagement. Information about the participant’s current role, background and research activi-
ties was also taken, in order to contextualise their responses.
The sampling frame for this study can be described as purposive [69]. The inclusion criteria
were: 1) the individual must have experience in developing PMF platforms and 2) be associated
with either the Pharma-Factory and/or Newcotiana projects. Individuals at the universities and
businesses belonging to the two consortiums were approached (by email) for involvement in
the study. Only consortium partners not directly involved in the development of PMF platforms
were excluded from the study. The sampling frame was chosen to provide a relatively quick
overview of the ‘state of play’ in PMF and NPBTs within these two large European projects.
Interviews were audio recorded and transcribed by a private company adhering to the UK
Data Protection Act and General Data Protection Regulations of the European Union.
Potential participants were informed of their prospective invitations to these informal inter-
views during the grant preparation phase. Audio consent was taken prior to the interview. Par-
ticipants of Pharma-Factory interviews were also invited to correct their transcripts
individually for errors and to ensure no commercially or otherwise sensitive data was collected.
All project partners were approached for comment on this article prior to submission. Ethical
approval for Newcotiana and Pharma-Factory public engagement work package activities was
given by the St George’s Research Ethics Committee (refs: SGREC18.0006; SGREC2018.0143).
Data analysis
The data analysis was undertaken in accordance with Framework Analysis, a thematic approach
developed by Jane Ritchie and Liz Spencer for large-scale policy work [66]. It is designed for
instances in which there are specific questions, a pre-designated sample (often professionals in
a given domain), limited timeframes and known a priori issues [70]. An initial coding frame-
work was developed by three researchers for both datasets via line-by-line open coding, after
which subsequent transcripts were coded and indexed using NVivo 12 for Windows.
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The coding and development of analytical themes was conducted separately for each of the
studies before a secondary, combined analysis was undertaken by cross-referencing analytical
themes and supporting evidence. This approach allowed for exploration of the complementari-
ties and potential differences in the data, which are outlined below. A list of codes and support-
ing data are provided alongside this article in the project repositories.
Findings
Between April and May 2018, Jonathan Menary (PhD) and Sara Mesquita de Albuquerque
(MSc), both research assistants with experience in qualitative interviewing, conducted 21 sepa-
rate interviews with participants (17 participants were interviewed by video conferencing or tele-
phone and four were interviewed face-to-face). In total, 51 people were approached for
interview. Those that did not respond to requests for interview after two emails were considered
to have refused to participate. One participant was present in both samples (due to representa-
tion on both projects)– 13 (61.9%; 13/21) were men and seven (33.3%; 7/21) were women. Six
participants (28.6%; 6/21) represented SMEs, being businesses with less than 250 employees (one
VP, two CEOs and two research scientists), six (28.6%; 6/21) were researchers at universities
(three professors, two senior researchers and one project manager) and eight (38% 8/21) were
researchers at public research institutions (four professors, three senior researchers and one PhD
student). Interviews lasted between 20–40 minutes for Newcotiana and 54–96 minutes for
Pharma-Factory. No respondents refused to answer any topic of enquiry that was posed to them.
In this section, the key findings of the research are outlined with reference to three key
themes that have emerged. Similar themes were identified in each study, with discussions
around NPBTs being somewhat dominant. The findings are presented in a combined manner,
but differences between the projects are noted where relevant.
The need for (careful) communication
For the researchers and companies working in the field of PMF and plant breeding, communi-
cation with others—particularly the public—was considered to key to improving the accept-
ability of the technology:
“. . . what we need to do is come to the public and explain to the public that. . . breeding is
even worse than genetic modification. I’m not sure that the common regular person in the
house is familiar with the real facts.”
Pharma-Factory SME representative (1)
A key finding showed that communicative activities often involved ‘contrast’, most com-
monly between NPBTs and conventional breeding techniques, which, in the case of mutagene-
sis, researchers stressed could be far less precise than NPBTs:
“The previous technology was like shotguns. Now we are using a laser to do exactly the same.”
Newcotiana researcher (6)
There was an assumption that the more information the public had about these technolo-
gies, the greater would be its support for their development:
“So when you explain to them these kinds of things, they are usually ready to accept such kind
of production.”
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Pharma-Factory researcher (5)
The same is true for PMF in general, where a need for contrast with existing protein expres-
sion systems was perceived to be an advantage for “greener”, plant-based production:
“. . . [plant molecular farming]is our interest, because getting products coming from plants is
like. . . a green source, so that’s completely okay and complies with our aim in the cosmetic
industry.”
Newcotiana cosmetic company representative (1)
Furthermore, effective communication of the benefits of PMF, including the potential
lower cost of plant-based expression and the need to focus on the products it can provide, was
considered to be important for the future of the technology:
“I’m really, really emphasising making pharmaceuticals, because the alternative is quite
expensive.”
Newcotiana researcher (3)
“. . . we shouldn’t spend so much time on technicalities. . . this won’t reach out very much to
the general public. If you can show that the products that are done by these techniques are
interesting, then that might be all that people care about.”
Newcotiana researcher (5)
Although this view contradicts the assumption that providing more information about bio-
technology (necessarily) leads to greater support for it, there was a perception that the purpose
of PMPs would improve the acceptability of genetic modification:
“. . .[modification] has a negative picture but if you use it for production of pharmaceuticals
then it completely changes.”
Newcotiana researcher (1)
There were reservations amongst several scientists about the extent to which lay people
would be able to fully appreciate what were described as “academic” differences between
NPBTs and the first-generation GM techniques that have caused controversy in the EU:
“I don’t’ believe that people will [see] a big difference between GMO and new plant breeding
techniques. In their minds, it’s more of this whole modern stuff, modern genetic manipulation.”
Newcotiana researcher (5)
One participant described a need for a “blockbuster success” in PMF to increase public
awareness of the technology. In providing information about NPBTs and PMF, the media was
held to be the most important actor(s), capable of shaping the public’s image of these emerging
technologies. It was also suggested that environmental non-governmental organisations
(NGOs) would oppose NPBTs, even for biopharmaceutical crops, based on historical
responses to GM technology in food:
“One of the main reasons Golden Rice has been sitting on the shelf for ten years is because
organisations such as Greenpeace came out and said ‘we cannot allow Golden Rice to go out
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because if we allow one product the floodgates will open’. As far as Greenpeace is concerned. . .
there is no difference between molecular farming, mutational improvement, agronomic traits,
or anything else. They would always, in my opinion, maintain this position—against.”
Pharma-Factory researcher (9)
There was also concern that the combination of genetic modification and the tobacco plant
could add to the stigma around an already stigmatised crop for the potential growers of PMF
crops. However, many more participants observed that PMF could actively improve the image
of the tobacco plant should it be used in the production of pharmaceutical products:
“I think less controversial definitely, definitely. I think that now the uses of tobacco are 99%
smoking. That is something that is not good for your health. . . and the aim of this project is to
have a new-cotiana, a new tobacco that changes completely the scope and the uses, instead of
being for smoking it’s used for more positive applications.”
Newcotiana researcher (2)
In summary, a strong emphasis was placed on the importance of communication with the
public in particular. Engagement of the media was seen to be paramount for enabling positive
communications about PMF. Many participants embraced the need for communication with
the public by speaking on public radio and at schools. There was a perception that a focus on
products—and their benefits—was an important focus for these communications. However, it
was also suggested that opposition to the use of NPBTs would persist amongst certain groups
regardless of purpose.
Regulatory environments tied to existing systems and definitions
The technical requirements of PMF are strictly tied to both current regulation and existing
protein expression systems. These current systems form a benchmark for quality assessment,
yet were also seen as a significant barrier:
“. . . it’s really easy and very clear what we need to demonstrate in order to be competitive.
You need to demonstrate that you can produce to the same quality and the same quality stan-
dards set by for example the pharmaceutical and food industry. It’s quite clear. It’s certain
ISO regulations, it’s the GMP [good manufacturing practice] regulations.”
PharmaFactory SME representative (3)
“But the CHO cells and bacteria are so established and there are so many examples where pro-
cesses have been approved by the regulatory agencies. . . it’s completely different with plants.”
Newcotiana researcher (1)
The lukewarm attitude of big pharmaceutical companies towards new sources of PMPs was
likewise noted as a potential barrier to the support for PMF:
“There had been a lot of resistance amongst the big pharmaceutical companies to actually
bring on line another production technology because they felt that that would compete with
their gold standard, which was transgenic mammalian cells in fermenters. . . perhaps this is
one of the reasons you haven’t seen more than one or two products of plant molecular farming
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on the market. And still big pharma is, at best, neutral; in a worst case scenario, skeptical or
even ambivalent about a plant production system.”
PharmaFactory researcher (9)
Plants were also promoted as a potentially safer platform for the production of PMPs:
“. . . the product will be safer if it’s produced in plants, because viruses in plants are not infect-
ing humans.”
Pharma-Factory SME representative (5)
It was suggested that the use of controlled environments for PMP production could improve
their regulatory standing and, it was also assumed, the social acceptability of genetic modification:
“The major difference is, first GM food is done in the open field, with all the risks that you
have. So plant molecular pharmaceutical is in containment. . . and the other thing is they
know they will get sick and they will need medicine.”
Pharma-Factory researcher (4)
If regulatory hurdles can be overcome, then competition from existing systems remains,
though it was noted that PMF will compete best in niches for which no alternative protein
expression systems exist:
“Because the field of protein production is quite competitive and so far plants only cover a
niche within this whole market. And are not really competitive to other systems like microbial
cells or mammalian cells.”
Newcotiana researcher (1)
The regulation of NPBTs was also of concern for participants, hinging on the classification
of genetic modification:
“In order to make gene editing, you have to introduce CRIPSPR-Cas protein, plus these guide
RNA. And one easy way to do it is to make a transgenic plant with the CRISPR-Cas gene, plus
the transgenic RNA gene. And that’s transgenic. There is no doubt about it. And then you
cross these out and you remain with a mutation. But as the European legislation works by
pedigree. . . anything that has been transgenic once is, according to the European legislation, is
transgenic forever. Even, if the transgene is not [there anymore].”
Newcotiana researcher (5)
In summary, there is evidence of both certainty and uncertainty around the regulatory envi-
ronment. Certain existing systems provide both a benchmark for PMPs and source of direct
competition. It is not clear to practitioners whether PMF will be considered for a distinctive
regulatory pathway, nor how NPBTs will be regulated in the future.
Legitimation of new plant breeding techniques
A further conceptual theme that related to the legitimation of NPBTs was identified. Partici-
pants pointed to various justifications for their use, such as by appealing to the long history of
domestication and cultivation of various crop plants by humans:
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“I [would] like [the public] to be able to put it in the context of all the breeding that has been
done, is doing, being done and have done for centuries. . . people, both farmers and general
public to understand that this, the changes produced are the same that we have been produc-
ing for many years, it’s only the tools we use are different and are more effective.”
Newcotiana researcher (2)
NPBTs were also considered to mimic more “natural” processes, such as gene silencing and
knockouts:
“I would say new plant breeding techniques, it’s no different to the natural variation. . . just
making base pair mutations to, for example in my case that knock-down gene. So those single
base pair [mutations] will occur, they can occur in nature.”
Newcotiana researcher (3)
In turn, these arguments fed into debates about the appropriate regulatory response by the
EU towards NPBTs:
“How should we do it, what should be the risk? How should we be able to regulate such things
if you cannot prove this thing is different from a natural plant?”
Newcotiana researcher (6)
In conclusion, the use of NPBTs is being legitimated by (pre-) history, precision and natu-
ralness. Interview themes across both projects overlapped considerably, though more emphasis
was placed on products and processes amongst the Pharma-Factory cohort and a greater focus
on public perception of NPBTs within the Newcotiana cohort.
Discussion
In this section, the findings are discussed with reference to the wider literature around plant
molecular farming, biotechnology and technological transitions. The results of the study have
confirmed several previous findings. The need for plant-specific policies to support PMF, for
example, has been noted by other commentators [56]. Some authors have also pointed to a
need for blockbuster successes in PMF [64], an observation echoed here. The need for these
elements of technological development appears to be well-described by the multi-level per-
spective, demonstrating its effectiveness at describing the factors that shape the trajectory of
new technologies. More surprising are the ways in which NPBTs are being legitimated by
experts and, in particular, the extent to which this legitimation is rooted in past debates about
plant breeding.
Public perception of biotechnology and communication
The findings suggest that communication is a vital component for the development of PMF
and NPBTs; there appears to be an almost inextricable link between the two at this level. Given
the scale of debate about biotechnology in Europe, public perception of the risks and benefits
of these new technologies (and their regulation) remains the first major obstacle for NPBT-
bred PMPs. The extent to which public opinion about biotechnology currently shape the regu-
latory stance of EU legislative structures is debatable. However, in the case of GM food, public
discourse has had a significant impact on the regulatory process [47] and it is through newspa-
pers, television and the internet that people form their first impressions of new technologies
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and the risks around them [46,71]. As such, our participants’ concerns over communication of
PMF and NPBTs—and the role of the media in mediating early perceptions of new technology
—appears to be well-founded.
The sometimes-contradictory views expressed in our findings with respect to what and how
to communicate biotechnology information mirror the intricacy of the relevant literature. The
assertion that “more information” about NPBTs would lead to greater acceptance, for example,
suggests that some participants subscribe to the knowledge deficit model. As Sturgis & Allum
[48] note: “implicit in this programmatic agenda is the claim that ‘to know science is to love
it’”. Yet participants themselves also displayed a deficit of knowledge when it comes to research
on public attitudes towards science. Most cited knowledge as a major barrier (i.e. the public do
not have enough) rather than, for example, negative views towards commercial involvement in
scientific studies [52].
As for the concern that the public would not see the “academic” differences between older
forms of genetic modification and NPBTs, survey data of European consumers shows that cis-
genic breeding is more acceptable than transgenic breeding [72,73], suggesting the public is
capable of understanding this distinction. Opinions vary across EU member states, however,
and have been shown to be tied more closely to purpose and potential benefit [73]. Connor &
Siegrist [51] also find that perceived benefit and risk are more significant determinants of pub-
lic opinion than knowledge, a claim also made by some participants in this study. As such,
providing consumers with sufficient and relevant information about biotechnology to make
informed choices based on potential benefits and risks should be promoted [47]; this view like-
wise re-orientates the emphasis from (public) knowledge deficits to better science communica-
tion and perhaps new forms of public engagement that align with the need for more
responsible research and innovation [see 74].
The benefits of PMF are perhaps inherently easier to communicate than those of NPBTs,
though taken together third-generation GM crops offer direct benefit to consumers, which
Breithaupt [75] argues could improve public perception of biotechnology (and their regulatory
standing). The perception of direct personal benefit appears to increase acceptance of genetic
modified food crops [76]. Many benefits of first-generation GM crops are found ‘upstream’ of
the consumer (herbicide tolerance and insect resistance) rather than in aspects of food quality
easily perceptible to the wider public [77]. As Sparrow et al. [78] note: “the early (agricultural)
products from large biotechnology companies were mistrusted and directly benefitted farmers
but not consumers”. Others see the benefits of GM food accruing to only the large multina-
tional agri-businesses that patent the crops in question [79]. The ability for NPBTs to provide
downstream benefits, such as high-value medical molecules, is therefore an important factor
for understanding social acceptance now and in the future.
PMF regulation and the socio-technical regime
In general, participants were explicit about what manufacturing standards needed to be met
for new PMF products to be successful (i.e. current GMP guidelines). The advantages of plant-
based protein production described by participants are not necessarily being realised yet, due
to the need to meet GMP guidelines, which have been developed with bacterial and mamma-
lian cell cultures in mind rather than being inclusive of plants [54,55]. Our findings also sug-
gest that significant prior investment in existing systems by firms may be deterring interest in
PMF platforms [63,see 80].
The observation that plants occupy several niches in which they do not directly compete
with established protein expression systems is also important; according to the MLP, these
niches represent proving grounds for PMF and permit the growth of early “blockbuster
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successes” [64] that participants believed would be required to raise PMF in the public
consciousness.
The findings also confirm a lack of landscape-level pressure on the existing regime. How-
ever, certain changes could provide opportunities for PMF to become a more established pro-
tein expression system, such as subsidies for PMPs, greater emphasis on quick production
times [63] and promotion of PMF as a ‘greener’ sources of medical molecules [81]. These ini-
tiatives would also align with the EU’s overarching ‘Bioeconomy Strategy’, which promotes
greener sources of industrial products [82]. Yet the ability to produce these molecules rapidly
could simply serve to reinforce the regime by providing a fast form of pharmaceutical testing
that precedes cell culture batch production [63]. A desire for greener products (as promoted
by one participant) could put pressure on existing protein expression systems, but this
assumption has several problems: 1) it assumes that consumers are familiar with how pharma-
ceuticals are currently produced, 2) that PMF is demonstrably more environmentally-friendly
than existing bioreactors and 3) it leaves the concept of PMF open to criticism from those who
have previously advocated against the diversion of food crops for other uses, as occurred with
biofuels in the EU [see 83]. The avoidance of food crops (e.g. using tobacco instead) and the
use of containment facilities circumvents this problem, but open-field PMF might be consid-
ered non-green where land suitable for food production is used for the production of non-
food crops. Other landscape-level pressures that could work against PMF include public accep-
tance of the technology and the use of NPBTs, as described above.
Legitimation of NPBTs
The findings demonstrate how experts are legitimating the use of NPBTs. Arguments for the
more lenient regulation of NPBTs, for example, rest on their precision and ability to induce
changes in plant genomes that are equivalent to natural processes (such as gene silencing); the
same arguments are used throughout the literature on NPBTs [84–86]. Parallels were also
drawn with existing plant breeding techniques, particularly chemical and radiative mutagene-
sis, which were described as plant breeding’s “shotgun” to the NPBT “laser”. Of course, an
appeal to the precision of NPBTs places emphasis on process and not product, despite calls
for the use of a product-based regulatory trigger for NPBT-bred plants in Europe [37].
Myskja et al. [87] argue that scientists do not see ‘naturalness’ as relevant to the debate
about the ethics of plant breeding; the invocation of naturalness in our sample may be an
appeal to the presumed perceptions of a public, that, at least in the EU, does see naturalness as
important [72]. The mimicry of natural processes lead Eriksson & Ammann [86] to argue that
genome editing can facilitate a transition in perception of what is natural in plant breeding by
situating it (conceptually) between transgenic techniques and more conventional breeding.
NPBTs were also described as simply the most recent of a series of technological advances that
connect the Agricultural Revolution (and plant domestication) to plant breeding today.
PMF with tobacco
In general, the coupling of PMF and NPBTs with the tobacco plant was seen to provide an
opportunity to improve the image of tobacco. For US consumers, support for genetically
modified tobacco was contingent on societal good [88]–however, given the scale of debate in
Europe over the use of GM crops, further research is required to determine European attitudes
towards PMF and whether it can genuinely represent a bridge to greater social acceptance of
these biotechnologies.
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Limitations and areas for future research
The relative homogeneity of the participants in this study—predominantly (12/21; 57%)
researchers at universities and public research institutes—has several limitations. Whilst this is
useful for providing an understanding of the views that experts have of the immediate regula-
tory barriers for PMF and the ways in which experts may or may not have engaged the public,
they are not necessarily conversant with the literature on public attitudes towards, for example,
genetic modification. Likewise, participants in this study were drawn from two H2020 projects,
limiting the scope of the study to Europe. Given differences in legislation and reported mea-
sures of public opinion between Europe and the United States, for example, this work cannot
be considered applicable to areas outside of Europe. A key area for future research will involve
determining the barriers and facilitators of PMF and NPBTs in low- and middle-income coun-
tries, given the potential benefits of both to developing nations [see 65]. There is also a need to
move towards public engagement activities that bring various stakeholder groups together in
order to facilitate two-way communication. The Pharma-Factory project is taking such an
approach to the development of PMF (see https://pharmafactory.org).
Conclusions
This study has outlined an approach to identifying the barriers and facilitators for scaling-up
PMF and NPBTs using an applied qualitative framework. It has identified public perceptions
of biotechnology, the existing regulatory environment and competition from other protein
expression systems as explicit barriers to scaling-up PMF and NPBTs. This study has sought to
contextualise these insights within the wider literature around PMF and NPBTs and pointed
towards useful conceptual frameworks—such as MLP—that could help researchers understand
the development of PMF in Europe. In particular, the lack of plant-specific regulation, land-
scape-level pressure on the existing regime of bacterial and mammalian protein expression sys-
tems and support from pharmaceutical companies may confine PMF to ‘niches’ for the
foreseeable future.
This article has described a number of possible facilitation mechanisms, such as science
communication focused on the benefits and purpose of PMF, which our participants identified
as important in leading to an improvement in the perception of genetic modification of plants
amongst the public. The study has also shown how scientists and other interested parties are
framing NPBTs to legitimate more favourable regulation, relying primarily on arguments of
precision, mimicry of natural processes and plant breeding heritage.
Lessons of the past can yield important insights into the way forward through current chal-
lenges. The main challenges at the intersection of PMF and NPBTs will likely be regulation
and the opinions of Europeans towards these technologies. As our participants have stated—
and has been realised in the past (e.g. GM crops)–these two topics are central to the scale-up
of new technologies. The top-down promotion of science and technology for its own sake has
not always been persuasive and, as the findings of this study indicate, scientists do not always
appear to be aware of the wider literature on acceptability. As such, there is a need for suffi-
cient and relevant information about new technologies alongside more active forms of public
engagement that link both researchers and other stakeholders. Hartley et al. [89] argue that
new agricultural biotechnology represents an opportunity to re-evaluate current governance
systems—it is hoped that our work can contribute to the socially-responsible governance of
the emerging fields of PMF and NPBTs.
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